UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

DPP-4 inhibitors

Baillière's Best Practice & Research in Clinical Endocrinology & Metabolism, 2007-12, Vol.21 (4), p.517-533

Ahrén, Bo, MD, PhD

2007

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2004-05, Vol.89 (5), p.2078-2084

2004

Link zum Volltext

Verfügbarkeit prüfen

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The New England journal of medicine, 2018-10, Vol.379 (17), p.1612-1620

2018

Link zum Volltext

Verfügbarkeit prüfen

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The New England journal of medicine, 2018-10, Vol.379 (17), p.1599-1611

2018

Link zum Volltext

Verfügbarkeit prüfen

The current landscape of nucleic acid therapeutics

Nature nanotechnology, 2021-06, Vol.16 (6), p.630-643

2021

Link zum Volltext

Verfügbarkeit prüfen

Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder

Annals of neurology, 2020-03, Vol.87 (3), p.347-356

2020

Link zum Volltext

Verfügbarkeit prüfen

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Journal of medicinal chemistry, 2013-07, Vol.56 (14), p.5979-5983

2013

Link zum Volltext

Verfügbarkeit prüfen

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

American journal of respiratory and critical care medicine, 2020-05, Vol.201 (10), p.1193-1208

2020

Link zum Volltext

Verfügbarkeit prüfen

Targeting p53 for the treatment of cancer

Seminars in cancer biology, 2022-02, Vol.79, p.58-67

2022

Link zum Volltext

Verfügbarkeit prüfen

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

European journal of endocrinology, 2002-05, Vol.146 (5), p.717

2002

Link zum Volltext

Verfügbarkeit prüfen

Current and future status of JAK inhibitors

The Lancet (British edition), 2021-08, Vol.398 (10302), p.803-816

2021

Link zum Volltext

Verfügbarkeit prüfen

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2021-01, Vol.35 (1), p.1-17

2021

Link zum Volltext

Verfügbarkeit prüfen

Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders

Journal of medicinal chemistry, 2018-10, Vol.61 (20), p.9062-9084

2018

Link zum Volltext

Verfügbarkeit prüfen

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Blood, 2019-04, Vol.133 (16), p.1742-1752

2019

Link zum Volltext

Verfügbarkeit prüfen

Buflomedil for intermittent claudication

Cochrane database of systematic reviews, 2008-01 (1), p.CD000988

2008

Link zum Volltext

Verfügbarkeit prüfen

Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition

Nature communications, 2016-11, Vol.7 (1), p.13312-13312, Article 13312

2016

Link zum Volltext

Verfügbarkeit prüfen

SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats

Toxicology and applied pharmacology, 2017-10, Vol.333, p.43-50

2017

Link zum Volltext

Verfügbarkeit prüfen

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2023-05, Vol.388 (18), p.1657-1667

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Clinical infectious diseases, 2018-09, Vol.67 (7), p.1010-1017

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment failure with DAA therapy: Importance of resistance

Journal of hepatology, 2021-06, Vol.74 (6), p.1472-1482

Sarrazin, Christoph

2021

Link zum Volltext

Verfügbarkeit prüfen

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

British journal of haematology, 2021-10, Vol.195 (2), p.244-248

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of the histamine H 4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis

Journal of allergy and clinical immunology, 2019-05, Vol.143 (5), p.1830

2019

Link zum Volltext

Verfügbarkeit prüfen

Preventive therapy for breast cancer: a consensus statement

The lancet oncology, 2011-05, Vol.12 (5), p.496-503

2011

Link zum Volltext

Verfügbarkeit prüfen

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

Journal of the American Society of Nephrology, 2014-05, Vol.25 (5), p.1083-1093

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.776

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.253)
Mit Volltextzugriff
(1.810)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(2.227)
Pyrrolidines - Therapeutic Use
(2.143)
Science & Technology
(1.815)
Life Sciences & Biomedicine
(1.770)
Male
(1.464)
Female
(1.184)
Middle Aged
(878)
Animals
(830)
Adult
(756)
Aged
(641)
Biological And Medical Sciences
(572)
Pyrrolidines - Pharmacology
(554)
Medical Sciences
(553)
Pharmacology & Pharmacy
(515)
Treatment Outcome
(397)
Pyrrolidines
(375)
Pyrrolidines - Adverse Effects
(375)
Rats
(367)
Pharmacology. Drug Treatments
(346)
Adamantane - Analogs & Derivatives
(330)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

DPP-4 inhibitors

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

The current landscape of nucleic acid therapeutics

Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

Targeting p53 for the treatment of cancer

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

Current and future status of JAK inhibitors

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Buflomedil for intermittent claudication

Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition

SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Treatment failure with DAA therapy: Importance of resistance

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Efficacy and safety of the histamine H 4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis

Preventive therapy for breast cancer: a consensus statement

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

Suchergebnisse filtern